Compound Comparisons
Side-by-side comparisons of the compound pairs readers most often confuse — separated by evidence, mechanism, and risk.
BPC-157 vs TB-500
BPC-157 and TB-500 are the two compounds most often discussed together in tissue-repair contexts — and they ar…
ComparisonSemaglutide vs Tirzepatide
Semaglutide and tirzepatide are the two most-studied incretin medicines, both approved for type 2 diabetes and…
ComparisonTirzepatide vs Retatrutide
Tirzepatide is an approved dual GIP/GLP-1 agonist; retatrutide is an investigational triple agonist adding glu…
ComparisonBPC-157 vs GHK-Cu
BPC-157 and GHK-Cu are both marketed for tissue repair and skin health, but they sit at different points on th…
ComparisonCagriSema (Cagrilintide + Semaglutide) vs Tirzepatide
CagriSema — the fixed-dose combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide — i…
ComparisonCJC-1295 vs Sermorelin
CJC-1295 and sermorelin both mimic GHRH, the hypothalamic signal that prompts natural growth hormone release —…
ComparisonIpamorelin vs CJC-1295
Ipamorelin and CJC-1295 are the two gray-market GH secretagogues most often sold together as a stack. They wor…
ComparisonMK-677 (Ibutamoren) vs HGH
MK-677 is an oral ghrelin-receptor agonist that raises growth hormone levels; somatropin is injected recombina…
ComparisonSemaglutide vs Liraglutide
Semaglutide and liraglutide are both approved GLP-1 receptor agonist medicines — liraglutide the first-generat…
ComparisonSemaglutide vs Retatrutide
Semaglutide is the most widely used GLP-1 medicine in the world; retatrutide is an investigational triple agon…
ComparisonTesamorelin vs CJC-1295
Tesamorelin and CJC-1295 are both GHRH-receptor agonists, which makes this comparison unusually clean: one com…